A securities class action alleges Aardvark Therapeutics overstated ARD-101's safety profile; Wall Street price targets collapsed from as high as $29 to $7 after the Phase 3 HERO trial was paused and the FDA imposed a clinical hold.
NEW YORK, Aug. 20, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (NASDAQ: AARD) and certain of its officers.
NEW YORK, Aug. 20, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD) and certain officers and directors.   The class action, filed in the United States District Court for the Southern District of California, and docketed under 26-cv-04643, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 13, 2025 (the "IPO" or "Offering"); and/or (b) Aardvark securities between February 13, 2025 and May 14, 2026, both dates inclusive (the "Class Period"). Plaintiff pursues claims against the Defendants under the Securities Act of 1933 and the Securities Exchange Act of 1934.
SAN FRANCISCO, Aug. 20, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit.
A securities class action alleges former Chief Operating Officer Bryan Jones, Ph.D. told investors in May 2025 that ARD-101 had a "very, very clean" safety profile, months before cardiac observations allegedly forced a Phase 3 pause and a full FDA clinical hold.
SAN FRANCISCO, Aug. 18, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit.
SAN DIEGO, Aug. 17, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLPÂ reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's February 13, 2025 initial public offering ("IPO") and/or (b) securities between February 13, 2025 and May 14, 2026 (the "Class Period"). Aardvark is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies designed to inhibit hunger and treat metabolic diseases such as Prader-Willi Syndrome ("PWS"), a neurodevelopmental disorder condition that presents hyperphagia, or a feeling of extreme, insatiable hunger.
NEW YORK, Aug. 17, 2026 /PRNewswire/ --
SAN FRANCISCO, July 30, 2026 /PRNewswire/ -- On May 15, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares significantly decline again – this time, the shares fell $2.16 (-32%). The decline was driven by news that the FDA placed a clinical hold on the company's Prader-Willi Syndrome ("PWS") asset.
SAN FRANCISCO, July 22, 2026 /PRNewswire/ -- On May 15, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares significantly decline again – this time, the shares fell $2.16 (-32%). The decline was driven by news that the FDA placed a clinical hold on the company's Prader-Willi Syndrome ("PWS") asset.
